References
- Jennette JC, Falk RJ, Andrassy K, Bacon P, Churg J, Gross WL, et al. Nomenclature of systemic vasculitis. Proposal of an inter-national consensus conference. Arthritis Rheum. 1994;37:187–92.
- Falk RJ, Hogan S, Carey TS, Jennette JC, the Glomerular Disease Collaborative Network. Clinical course of antineutrophil cyto-plasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med. 1990;113:656–63.
- Geffriand-Ricouard C, Noel LH, Chauveau D, Houhou S, Grundfeld JP, Lesavre P. Clinical spectrum associated with ANCA defined antigen specificities in 98 selected patients. Clin Nephrol. 1993;39: 125–36.
- Hogan S, Nachman PH, Wilkman AS, Jennette JC, Falk RJ, the Glomerular Disease Collaborative Network. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associ-ated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:23–32.
- Westman KWA, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998;9:842–52.
- Bajema IM, Hogan EC, Hermans J, Noel LH, Waldherr R, Fer-rario F, et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int. 1999;56:1751–8.
- Kawamoto S, Kawamura T, Utsunomiya Y, Kawaguchi Y, Ho-soya T. Analysis of risk factor for patients and renal survival in anti-myeloperoxidase antibody (MPO-ANCA) associated glo-merulonephritis (in Japanese, abstract in English). Jpn J Nephrol. 1999;41:719–25.
- Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopatho-logical analysis of 96 patients. Kidney Int. 2002;62:1732–42.
- Japanese Study Group for MPO-ANCA-Associated Vasculitis (JMAAV). The prospective cohort study for MPO-ANCA asso-ciated vasculitis treated according to the standard protocol regi-men (directed by Prof S.Ozaki, in Japanese). 2006 Annual Report on Intractable Vasculitis Syndrome supported by the Ministry of Health, Welfare, and Labour of Japan; 2006. pp. 199–273.
- Nagakawa T, Arimura Y, Yoshida M, Hiromura N, Naruse T, Nishiki N, et al. Fundamental and clinical evaluation of MPO ELISA kit (NISSHO) (in Japanese). Lab Mach Reag. 1995; 18:127–35.
- Gordon M, Luqmani RA, Adu D, Greaves I, Richards N, Michael J, et al. Relapses in patients with a systemic vasculitis. Q J Med. 1993;86:779–89.
- Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic auto-antibody associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:33–4.
- Nakabayashi K, Kobayashi S, Matsuoka Y, Yoshida T, Yoshida M, Ozaki S, et al. Statistical analysis of infectious death in patients receiving immunosuppressive drugs with medium-and small-vessel vasculitides (in Japanese, abstract in English). 2000 Annual Report for the Refractory Vasculitis Syndrome (Chief: prof H. Hashimoto) supported by Ministry of Health, Welfare, and Labour of Japan; 2001. pp. 58–68.
- Sakai H, Kurokawa K, Koyama T, Arimura Y, Kida H, Shig-ematsu S, et al. The treatment guideline for rapidly progressive glomerulonephritis (in Japanese). Jpn J Nephrol. 2002;44:55–82.
- Fujii A, Tomizawa K, Arimura Y, Nagasawa T, Uhashi YY, Hiyama S, et al. Epitope analysis of myeloperoxidase (MPO) specific anti-neutrophil cytoplasmic autoantibodies (ANCA) in MPO-ANCA-associated glomerulonephritis. Clin Nephrol. 2000; 53:242–52.